Lexaria Bioscience Corp. Files 8-K on Shareholder Vote Matters

TL;DR

Lexaria Bioscience Corp. (LXRP) filed an 8-K regarding a shareholder vote. Keep an eye on developments.

AI Summary

Lexaria Bioscience Corp. filed an 8-K on January 15, 2025, reporting on a submission of matters to a vote of security holders. The filing details events that occurred on January 14, 2025, and was submitted as of January 15, 2025. The company is incorporated in Nevada and its principal executive offices are located in Kelowna, BC, Canada.

Why It Matters

This filing indicates that Lexaria Bioscience Corp. is engaging in a process that requires a vote from its security holders, which could impact corporate governance or strategic decisions.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a submission for a security holder vote, not an indication of immediate financial distress or significant operational change.

Key Players & Entities

• Lexaria Bioscience Corp. (company) — Registrant
• January 14, 2025 (date) — Earliest event reported
• January 15, 2025 (date) — Date of report and filing
• Nevada (jurisdiction) — State of incorporation
• Kelowna, BC Canada (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common

Filing Documents

• lxrp_8k.htm (8-K) — 60KB
• 0001640334-25-000087.txt ( ) — 199KB
• lxrp-20250114.xsd (EX-101.SCH) — 6KB
• lxrp-20250114_lab.xml (EX-101.LAB) — 16KB
• lxrp-20250114_cal.xml (EX-101.CAL) — 1KB
• lxrp-20250114_pre.xml (EX-101.PRE) — 12KB
• lxrp-20250114_def.xml (EX-101.DEF) — 4KB
• lxrp_8k_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders On January 14, 2025 at 1:00 p.m. (Pacific Time), the Company held its annual and special shareholder meeting (the "Meeting"). There were 9,761,279 shares of the Company represented in person or by proxy at the Meeting, constituting 55.93% of the Company's issued share capital as at November 18, 2024, being the record date of the Meeting. The matters voted upon at the Meeting and the final voting results are set forth below: Matter Being Voted On For Against/ Withheld Abstain Broker Non-Vote Percent Approved By 1 To Elect Chris Bunka as a director 5,168,004 608,879 - 3,984,396 89 % To Elect John Docherty as a director 5,635,178 141,705 - 3,984,396 98 % To Elect Nicholas Baxter as a director 3,600,923 2,177,149 - 3,983,207 62 % To Elect Ted McKechnie as a director 3,100,882 2,677,190 - 3,983,207 54 % To Elect Albert Reese Jr. as a director 5,208,406 569,666 - 3,983,207 90 % To Elect Richard Christopher as a director 5,682,948 95,124 - 3,983,207 98 % To Elect Bal Bhullar as a director 5,679,731 98,341 - 3,983,207 98 % To Appoint Malone Bailey LLP as Auditors 9,544,943 192,543 27,793 - 98 % To Approve Executive Compensation 5,580,530 150,814 46,727 3,983,208 97 % To Approve Executive Compensation Annually 2 1,828,002 - 119,054 3,983,207 32 % To Approve Executive Compensation every two years 45,224 - 119,054 3,983,207 1 % To Approve Executive Compensation every three years 3,785,792 - 119,054 3,983,207 66 % To Approve the Warrant Exercise Proposal 4,024,010 1,663,342 90,719 3,983,208 70 % To Ratify the lawful actions of the directors for the past year 5,268,595 412,730 96,747 3,983,207 91 % 1 Percentage is calculated based on abstained votes and broker non-votes not being counted as a vote against the resolution. 2 The timing for the approval of the e

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEXARIA BIOSCIENCE CORP. /s/ Richard Christopher Richard Christopher CEO, Principal Executive Officer Date: January 15, 2025 3